RxSight, Inc. Amends Credit Agreement
Ticker: RXST · Form: 8-K · Filed: May 9, 2024 · CIK: 1111485
| Field | Detail |
|---|---|
| Company | Rxsight, Inc. (RXST) |
| Form Type | 8-K |
| Filed Date | May 9, 2024 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.001, $56.00, $93.2 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: credit-agreement, amendment, financing
TL;DR
RxSight just amended its credit deal with MidCap Financial Trust. Details TBD.
AI Summary
On May 8, 2024, RxSight, Inc. entered into a Material Definitive Agreement, specifically a Second Amendment to the Credit Agreement, with MidCap Financial Trust, as administrative agent. This amendment modifies the existing credit facility, though specific financial terms of the amendment are not detailed in this filing.
Why It Matters
This amendment to RxSight's credit agreement could impact its financial flexibility and borrowing capacity, potentially affecting future operational and strategic decisions.
Risk Assessment
Risk Level: medium — Amendments to credit agreements can signal changes in a company's financial health or strategic needs, warranting closer examination of the specific terms.
Key Players & Entities
- RxSight, Inc. (company) — Registrant
- MidCap Financial Trust (company) — Administrative Agent and Lender
- May 8, 2024 (date) — Date of earliest event reported
FAQ
What are the specific changes to the Credit Agreement resulting from the Second Amendment?
The filing states that the Second Amendment to the Credit Agreement was entered into on May 8, 2024, but the specific details and financial implications of the amendments are not provided in this 8-K filing.
Who is MidCap Financial Trust in relation to RxSight, Inc.?
MidCap Financial Trust is identified as the administrative agent and a lender under the Credit Agreement that RxSight, Inc. has amended.
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report the entry into a Material Definitive Agreement, specifically the Second Amendment to the Credit Agreement.
When was the Second Amendment to the Credit Agreement effective?
The earliest event reported in the filing is dated May 8, 2024, indicating the Second Amendment to the Credit Agreement was entered into on or around this date.
Does this filing provide details on any new financial obligations or covenants for RxSight, Inc.?
No, this 8-K filing announces the amendment but does not provide specific details regarding new financial obligations or covenants resulting from the Second Amendment.
Filing Stats: 1,325 words · 5 min read · ~4 pages · Grade level 12.9 · Accepted 2024-05-09 16:41:04
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share RXST The Nasdaq Stock Mar
- $56.00 — s were sold at a price to the public of $56.00 per share. Under the terms of the Under
- $93.2 million — mpany, are expected to be approximately $93.2 million. The shares of Common Stock are being
Filing Documents
- d832746d8k.htm (8-K) — 33KB
- d832746dex11.htm (EX-1.1) — 209KB
- d832746dex51.htm (EX-5.1) — 13KB
- d832746dex991.htm (EX-99.1) — 9KB
- g832746dsp52.jpg (GRAPHIC) — 5KB
- g832746dsp55.jpg (GRAPHIC) — 2KB
- 0001193125-24-135328.txt ( ) — 457KB
- rxst-20240508.xsd (EX-101.SCH) — 3KB
- rxst-20240508_lab.xml (EX-101.LAB) — 17KB
- rxst-20240508_pre.xml (EX-101.PRE) — 11KB
- d832746d8k_htm.xml (XML) — 3KB
Forward-Looking Statements
Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this Current Report on Form 8-K that do not relate to matters of historical fact should be considered forward-looking statements. Forward-looking statements are subject to known and unknown risks and uncertainties, many of which may be beyond our control. Investors should review the risks and uncertainties contained in our filings with the SEC, including our Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, filed with the SEC on May 6, 2024, as well as other risks set forth in our other filings with the SEC. We caution you that the forward-looking information presented in this Current Report on Form 8-K is not a guarantee of future events, and that actual events may differ materially from those described in or suggested by the forward-looking information contained in this Current Report on Form 8-K. In addition, forward-looking statements generally can be identified by the use of forward-looking terminology such as "may," "will," "should," "could," "would," "expects," "plans," "intends," "anticipates," "believes," "estimates," "predicts," "projects," "potential," or "continue" or the negative of such terms and other similar terminology. Any forward-looking information presented herein is made only as of the date of this Current Report on Form 8-K, and we do not undertake any obligation to update or revise any forward-looking information to reflect changes in assumptions, the occurrence of unanticipated events, or otherwise. Item9.01
Financial Statements and Exhibits
Financial Statements and Exhibits. Exhibit No. Description 1.1 Underwriting Agreement, dated as of May 8, 2024 by and between the Company and BofA Securities, Inc., as representative of the several underwriters 5.1 Opinion of Wilson Sonsini Goodrich & Rosati, P.C. 23.1 Consent of Wilson Sonsini Goodrich & Rosati, P.C. (included in Exhibit 5.1 hereto) 99.1 Press Release, dated May 8, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. RxSight, Inc. Date: May 9, 2024 By: /s/ Shelley Thunen Shelley Thunen Chief Financial Officer